Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Teduglutide (Revestive®) in Adult and Pediatric Patients With Short Bowel Syndrome in Argentina
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Short Bowel Syndrome
- Sponsor
- Takeda
- Enrollment
- 45
- Locations
- 1
- Primary Endpoint
- Number of Participants With Adverse Events of Special Interest (AESI)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The main aims of the study are to assess the safety profile of Teduglutide (Revestive®) in people with Short Bowel Disease as well as how well people respond to the treatment with Teduglutide (Revestive®).
This study is about collecting data only; participants receive Teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. Only standard care information available in the participant's medical records will be reviewed and collected for this study.
Participants do not need to visit their doctor in addition to their normal visits.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult participants (greater than or equal to \[\>=\] 18 years) or pediatric (\>= 1 year and less than \[\<\] 18) with a diagnosis of SBS who are dependent on parenteral support.
- •Have received at least one dose of teduglutide according to approved indications.
- •Signed the mandatory consent that has been agreed with national regulatory authorities (ANMAT) as applicable.
Exclusion Criteria
- •Not Applicable.
Outcomes
Primary Outcomes
Number of Participants With Adverse Events of Special Interest (AESI)
Time Frame: Up to 24 months
AESI will include biliary disorders and cholecystitis; pancreatic disease; cardiovascular adverse events associated with fluid overload; intestinal obstruction; stoma complications; malignancy; gastrointestinal neoplastic growth, including colorectal polys and small bowel neoplasia; adverse events associated with increased absorption of concomitant oral medications; anxiety; injection site reactions and suspected immunogenic reactions (like hypersensitivity or other reactions); embryo-fetal toxicity (assessed through follow up of all pregnancies).
Number of Participants With Adverse Events (AEs)
Time Frame: Up to 24 months
An AE is any untoward medical occurrence in a participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. A serious adverse events (SAEs) is any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, congenital abnormality/birth defect, an important medical event. Number of participants with AEs including serious and non-serious AEs will be assessed.
Secondary Outcomes
- Percentage of Participants With Clinical Response at Week 12 and 24(Week 12 and 24)
- Change From Baseline in Weekly Parenteral Support Volume at Week 12 and 24(Baseline, Week 12 and 24)
- Change From Baseline in Number of Days per Week of Parenteral Support at Week 12 and 24(Baseline, Week 12 and 24)